Production (Stage)
Lipella Pharmaceuticals Inc.
LIPO
$2.99
-$0.10-3.24%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.88% | 19.31% | 0.77% | 35.00% | 77.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.88% | 19.31% | 0.77% | 35.00% | 77.51% |
| Cost of Revenue | 18.08% | 18.90% | -1.88% | -3.08% | 74.88% |
| Gross Profit | -19.70% | -18.83% | 2.38% | 8.80% | -74.43% |
| SG&A Expenses | -10.25% | -7.09% | 2.49% | 60.71% | 238.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.61% | 8.11% | -0.27% | 15.97% | 67.05% |
| Operating Income | -6.39% | -7.05% | 0.38% | -14.06% | -66.10% |
| Income Before Tax | -8.18% | -8.60% | 0.71% | -12.44% | -62.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.18% | -8.60% | 0.71% | -12.44% | -62.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.18% | -8.60% | 0.71% | -12.44% | -62.02% |
| EBIT | -6.39% | -7.05% | 0.38% | -14.06% | -66.10% |
| EBITDA | -57.08% | -143.47% | -221.09% | -- | -- |
| EPS Basic | 32.77% | 23.99% | 28.26% | 12.92% | -18.37% |
| Normalized Basic EPS | 32.77% | 23.99% | 28.26% | 12.92% | -18.37% |
| EPS Diluted | 32.95% | 24.60% | 28.72% | 13.55% | -18.08% |
| Normalized Diluted EPS | 32.77% | 23.99% | 28.26% | 12.92% | -18.37% |
| Average Basic Shares Outstanding | 67.03% | 39.64% | 41.49% | 37.15% | 41.08% |
| Average Diluted Shares Outstanding | 67.03% | 39.64% | 41.49% | 37.15% | 41.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |